Core Viewpoint - MicroPort Medical (00853) reported HeartCare Medical (688016.SH) 2025 annual performance forecast, showing total revenue of approximately 1.351 billion yuan, a year-on-year increase of 11.96%, and a net profit attributable to the parent company of approximately 563 million yuan, a year-on-year increase of 12.17% [1] Group 1: Financial Performance - Total revenue for the year is approximately 1.351 billion yuan, reflecting a year-on-year growth of 11.96% [1] - Net profit attributable to the parent company is approximately 563 million yuan, with a year-on-year increase of 12.17% [1] - Basic earnings per share stand at 4.65 yuan [1] Group 2: Market Strategy and Sales - The company has strengthened its domestic leading position through strategies such as market penetration, customized treatment solutions, and product upgrades, leading to a steady increase in market share [1] - Overseas sales revenue exceeded 250 million yuan, representing a growth of over 55%, contributing to more than 18% of total revenue [1] - The company is actively promoting its products in Europe, Latin America, and Asia-Pacific, with sales coverage extending to 49 countries and regions [1] Group 3: Product Development and Approvals - Multiple innovative products have been approved for launch in China, including the Cratos branched aortic stent graft system and other medical kits [2] - A total of 23 products have received NMPA registration, and 11 products have been registered in 28 overseas markets [2] - The company has a rich pipeline of products under development, with several products entering various stages of clinical trials and regulatory submissions [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 1 股東及投資者請注意，以上財務資料根據中國會計準則編製，並僅與心脈醫療科技的業務有關，而 與本集團其他附屬公司無關。該等資料未經審核，且(a)並未撇除集團內交易，(b)並不包括本集團所 有業務，及(c)並不代表或全面反映本集團業務或狀況。 本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 微創醫療科學有限公司* 上海微創心脈醫療科技（集團）股份有限公司 截至二零二五年十二月三十一日止十二個月未經審核財務資料 以下所載為上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）截至二零二五年十二月 三十一日止十二個月的未經審核財務資料。本公司持有心脈醫療科技40.32%的股權，其業績於本公 司財務報表合併入賬。心脈醫療科技的股份在上海證券交易所科創板上市。 | | 截至 | 截至 | | | --- | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 海外監管公告 常兆華博士 主席 本海外監管公告乃根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.10B條刊 發。 請參閱隨附上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）於上海證券交易所科創板 （「科創板」）刊發之公告（「該公告」），內容有關其二零二五年年度業績快報公告。 心脈醫療科技為一家於科創板上市之公司。於本公告日期，本公司持有心脈醫療科技已發行股本約 40.32%及其業績於本公司財務報表合併入賬。 於聯交所網站登載該公告，僅為向香港投資者進行同等的資訊傳達及遵守上市規則第13.10B條，別 無其他目的。 承董事會命 中國上海，二零二六年二月二十七日 於本公告日期，本公司之執行董事為常兆華博士；本公司之非執行董事為谷峰博士、門慶兵博士及 孫維琴女士；及本公司之獨立非執行董事為 ...

Core Viewpoint - Southbound funds have significantly increased their holdings in MicroPort Scientific Corporation (00853.HK), indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Southbound Fund Activity - On February 26, southbound funds increased their holdings by 1.6111 million shares of MicroPort Scientific Corporation [1] - Over the past five trading days, there have been four days of net increases, totaling 2.4247 million shares [1] - In the last 20 trading days, there were 15 days of net increases, amounting to 18.428 million shares [1] - Currently, southbound funds hold 926 million shares of MicroPort Scientific Corporation, representing 48.28% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business Division, which includes implantable devices and access devices [1] - Orthopedic Medical Devices Business Division, focusing on joint reconstruction and spinal devices [1] - Cardiac Rhythm Management (CRM) Business Division, which includes pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business Division, featuring products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business Division, dealing with cerebral artery atherosclerosis and coils [1] - Structural Heart Disease Business Division, which includes transcatheter aortic valve implantation [1] - Surgical Robotics Business Division, involved in the manufacturing and R&D of surgical robotic devices [1] - Surgical Medical Devices Business Division, focusing on the manufacturing and R&D of surgical medical devices [1]

Core Viewpoint - Southbound funds increased their holdings in MicroPort Scientific Corporation (00853.HK) by 242,100 shares on February 23, indicating a positive sentiment towards the company despite some fluctuations in the previous trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, there were 2 days of net reductions in holdings by southbound funds, totaling a net decrease of 915,800 shares [1] - Over the past 20 trading days, southbound funds increased their holdings on 15 days, with a cumulative net increase of 16,929,900 shares [1] - Currently, southbound funds hold 924 million shares of MicroPort, accounting for 48.21% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1] - Key products include implantable devices, surgical robots, and various instruments for cardiovascular and orthopedic applications [1]

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 1.4415 million shares on February 13, with net increases recorded on 4 out of the last 5 trading days, totaling 676,500 shares [1] - Over the past 20 trading days, there have been net increases on 15 days, amounting to 20.3817 million shares [1] - Currently, southbound funds hold 926 million shares of MicroPort Medical, representing 48.26% of the company's total issued ordinary shares [1] Company Overview - MicroPort Medical Science Co., Ltd. is primarily engaged in the sales, production, research, and development (R&D) of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business: Products include implantable devices and access devices [1] - Orthopedic Medical Devices: Focuses on joint reconstruction and spinal devices [1] - Cardiac Rhythm Management (CRM): Includes pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business: Features products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business: Involves products for carotid artery atherosclerosis and coils [1] - Structural Heart Disease Business: Engages in transcatheter aortic valve implantation [1] - Surgical Robotics Business: Manufactures and develops surgical robotic devices [1] - Surgical Medical Devices Business: Focuses on the manufacturing and R&D of surgical medical devices [1]

Group 1 - Morgan Stanley increased its stake in MicroPort Scientific Corporation (00853) by 891,713 shares at a price of HKD 11.089 per share, totaling approximately HKD 9.8882 million [1] - Following the increase, Morgan Stanley's total shareholding in MicroPort is approximately 192 million shares, representing a stake of 10.02% [1]

Core Viewpoint - Morgan Stanley has increased its stake in MicroPort Scientific Corporation (00853) by acquiring 891,713 shares at a price of HKD 11.089 per share, totaling approximately HKD 9.8882 million, resulting in a new holding of about 192 million shares, representing 10.02% ownership [1] Summary by Category Company Actions - Morgan Stanley's recent purchase of 891,713 shares indicates a strategic move to increase its investment in MicroPort Scientific Corporation [1] - The total investment made by Morgan Stanley amounts to approximately HKD 9.8882 million [1] Shareholding Structure - Following the acquisition, Morgan Stanley's total shareholding in MicroPort Scientific Corporation has reached approximately 192 million shares [1] - The increased stake now accounts for 10.02% of the total shares outstanding [1]

Core Viewpoint - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 601,000 shares on February 12, indicating a positive sentiment towards the company despite some days of net reductions in holdings [1] Group 1: Southbound Fund Activity - Over the past five trading days, there were two days of net reductions in holdings, totaling 2,280,500 shares [1] - In the last 20 trading days, southbound funds increased their holdings on 15 days, with a total net increase of 23,386,700 shares [1] - Currently, southbound funds hold 924 million shares of MicroPort Medical, accounting for 48.19% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Core Viewpoint - Southbound funds have reduced their holdings in MicroPort Scientific Corporation (00853.HK) by 1.72 million shares on February 11, with a total net reduction of 2.70 million shares over the past five trading days [1] Group 1: Shareholding Changes - In the last 20 trading days, southbound funds have increased their holdings on 14 days, resulting in a total net increase of 22.13 million shares [1] - Currently, southbound funds hold 924 million shares of MicroPort, accounting for 48.16% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]